Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18995928 | 0.93 | ALDH1A1 (0.62) | ALDH1A1MAPK1SLC6A7L3MBTL1MAPT | |
| SCHEMBL19001365 | 0.88 | SLC6A7 (0.71) | ALDH1A1MAPK1SLC6A7L3MBTL1MAPT | |
| SCHEMBL25010218 | 0.85 | ALDH1A1 (0.76) | ALDH1A1MAPK1SLC6A7L3MBTL1MAPT | |
| SCHEMBL1458671 | 0.83 | ALDH1A1 (0.57) | ALDH1A1MAPK1SLC6A7L3MBTL1MAPT | |
| SCHEMBL20467485 | 0.82 | HPGD (0.97) | ALDH1A1MAPK1L3MBTL1MAPTHPGD | |
| SCHEMBL8154101 | 0.82 | SLC6A7 (1.00) | ALDH1A1MAPK1SLC6A7L3MBTL1MAPT | |
| SCHEMBL18995987 | 0.82 | SLC6A7 (0.64) | ALDH1A1MAPK1SLC6A7L3MBTL1MAPT | |
| SCHEMBL13601160 | 0.81 | ALDH1A1 (0.79) | ALDH1A1MAPK1SLC6A7L3MBTL1HPGD | |
| SCHEMBL15583893 | 0.81 | HPGD (1.00) | ALDH1A1MAPK1MAPTHPGDMEN1 | |
| SCHEMBL20467460 | 0.81 | HPGD (1.00) | ALDH1A1MAPK1MAPTHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041576-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-02-09 | — | — | US | disclosed |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041576-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | NFKBIA, IKBKB, NFKB2 | ALDH1A1 4286/4885MAPK1 997/4885SLC6A7 4328/4885 |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NAMPT, NQO2, NNMT | ALDH1A1 1374/4885MAPK1 2199/4885SLC6A7 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.